Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 9, 2009

SARcode Pays $2M for Sunesis’ LFA-1 Inhibitor Program

  • SARcode bought Sunesis Pharmaceuticals' intellectual property and assets related to the LFA-1 inhibitor program for $2 million. The lead candidate, SAR 1118, which has yet to begin Phase I testing, is a small molecule LFA-1 inhibitor being developed for T-cell mediated ophthalmic diseases.

    SARcode previously had a license to this program. The license agreement will now be terminated, and Sunesis will forego future milestone payments and royalties.

    “Consistent with our strategy to focus our resources on advancing voreloxin, our novel investigational anticancer drug candidate currently being developed for acute myeloid leukemia and ovarian cancer, we made the decision to monetize our milestone and royalty rights in SARcode's LFA-1 program,” says Daniel Swisher, CEO of Sunesis. Voreloxin is in Phase II trials.

    “We have been impressed with the progress of SAR 1118 to date and retain an interest in the future success of this program through our convertible notes.” The convertible notes have a total principal value of $1 million.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »